We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · August 15, 2018

Meaningful Activity of Poziotinib in HER2+ MBC After ≥2 Prior HER2-Directed Regimens

International Journal of Cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

International Journal of Cancer
A Phase II Trial of the Pan-HER Inhibitor Poziotinib, in Patients With HER2-Positive Metastatic Breast Cancer Who Had Received at Least Two Prior HER2-Directed Regimens: Results of the NOV120101-203 Trial
Int. J. Cancer 2018 Jul 06;[EPub Ahead of Print], YH Park, KH Lee, JH Sohn, KS Lee, KH Jung, JH Kim, KH Lee, JS Ahn, TY Kim, GM Kim, IH Park, SB Kim, SH Kim, HS Han, YH Im, JH Ahn, JY Kim, J Kang, SA Im

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading